IXICO PLC (IXI) - Net Assets
Based on the latest financial reports, IXICO PLC (IXI) has net assets worth GBX10.72 Million GBX (≈ $1.30K USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX12.99 Million ≈ $1.58K USD) and total liabilities (GBX2.27 Million ≈ $276.19 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is IXICO PLC's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX10.72 Million |
| % of Total Assets | 82.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2.25% |
| 10-Year Change | 187.32% |
| Growth Volatility | 135.7 |
IXICO PLC - Net Assets Trend (1993–2025)
This chart illustrates how IXICO PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see IXI market cap overview.
Annual Net Assets for IXICO PLC (1993–2025)
The table below shows the annual net assets of IXICO PLC from 1993 to 2025. Also explore net asset growth rate of IXICO PLC to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | GBX11.74 Million ≈ $1.43K |
+24.02% |
| 2024-09-30 | GBX9.46 Million ≈ $1.15K |
-17.21% |
| 2023-09-30 | GBX11.43 Million ≈ $1.39K |
-8.49% |
| 2022-09-30 | GBX12.49 Million ≈ $1.52K |
+8.83% |
| 2021-09-30 | GBX11.48 Million ≈ $1.40K |
+25.88% |
| 2020-09-30 | GBX9.12 Million ≈ $1.11K |
+15.15% |
| 2019-09-30 | GBX7.92 Million ≈ $963.51 |
+8.09% |
| 2018-09-30 | GBX7.33 Million ≈ $891.36 |
+172.44% |
| 2017-09-30 | GBX2.69 Million ≈ $327.17 |
-34.17% |
| 2016-09-30 | GBX4.08 Million ≈ $497.03 |
+50.79% |
| 2015-09-30 | GBX2.71 Million ≈ $329.61 |
-28.93% |
| 2014-09-30 | GBX3.81 Million ≈ $463.81 |
+6.15% |
| 2013-09-30 | GBX3.59 Million ≈ $436.92 |
-57.12% |
| 2012-09-30 | GBX8.37 Million ≈ $1.02K |
-47.55% |
| 2011-09-30 | GBX15.96 Million ≈ $1.94K |
-32.00% |
| 2010-09-30 | GBX23.48 Million ≈ $2.86K |
+648.42% |
| 2009-09-30 | GBX3.14 Million ≈ $381.68 |
-56.19% |
| 2008-09-30 | GBX7.16 Million ≈ $871.29 |
+155.66% |
| 2007-09-30 | GBX2.80 Million ≈ $340.80 |
-56.77% |
| 2006-08-31 | GBX6.48 Million ≈ $788.31 |
-45.16% |
| 2005-08-31 | GBX11.81 Million ≈ $1.44K |
+123.24% |
| 2004-08-31 | GBX5.29 Million ≈ $643.88 |
+3.83% |
| 2003-08-31 | GBX5.10 Million ≈ $620.16 |
-50.44% |
| 2002-08-31 | GBX10.29 Million ≈ $1.25K |
-21.44% |
| 2001-08-31 | GBX13.09 Million ≈ $1.59K |
+175.04% |
| 2000-08-31 | GBX4.76 Million ≈ $579.15 |
+131.07% |
| 1999-08-31 | GBX2.06 Million ≈ $250.64 |
-30.26% |
| 1998-08-31 | GBX2.95 Million ≈ $359.42 |
-54.40% |
| 1997-08-31 | GBX6.48 Million ≈ $788.19 |
-32.12% |
| 1996-08-31 | GBX9.54 Million ≈ $1.16K |
+478.69% |
| 1995-08-31 | GBX-2.52 Million ≈ $-306.61 |
+6.98% |
| 1994-08-31 | GBX-2.71 Million ≈ $-329.61 |
-429.10% |
| 1993-08-31 | GBX-512.00K ≈ $-62.30 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IXICO PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8359600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX927.00K | 7.90% |
| Other Comprehensive Income | GBX7.36 Million | 62.70% |
| Other Components | GBX88.06 Million | 750.24% |
| Total Equity | GBX11.74 Million | 100.00% |
IXICO PLC Competitors by Market Cap
The table below lists competitors of IXICO PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CARLYLE COMMODIT.CORP.
F:BJ4
|
$199.86K |
|
Manolete Partners PLC
LSE:MANO
|
$199.89K |
|
Zinc Media Group
LSE:ZIN
|
$200.31K |
|
Premier Health of America Inc
V:PHA
|
$200.79K |
|
Ground Rents Income Fund PLC
LSE:GRIO
|
$197.88K |
|
Conygar Investment Co PLC
LSE:CIC
|
$197.37K |
|
Gladstone Land Corporation 6.00% Series C Cumulative Redeemable Preferred Stock
NASDAQ:LANDP
|
$196.14K |
|
QUICKBIT EU AB O.N.
F:QBT
|
$195.88K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IXICO PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,464,000 to 11,737,000, a change of 2,273,000 (24.0%).
- Net loss of 1,651,000 reduced equity.
- New share issuances of 3,697,000 increased equity.
- Other factors increased equity by 227,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.65 Million | -14.07% |
| Share Issuances | GBX3.70 Million | +31.5% |
| Other Changes | GBX227.00K | +1.93% |
| Total Change | GBX- | 24.02% |
Book Value vs Market Value Analysis
This analysis compares IXICO PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 57.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-08-31 | GBX-0.91 | GBX7.50 | x |
| 1994-08-31 | GBX-4.83 | GBX7.50 | x |
| 1995-08-31 | GBX-4.49 | GBX7.50 | x |
| 1996-08-31 | GBX15.74 | GBX7.50 | x |
| 1997-08-31 | GBX7.69 | GBX7.50 | x |
| 1998-08-31 | GBX3.48 | GBX7.50 | x |
| 1999-08-31 | GBX2.32 | GBX7.50 | x |
| 2000-08-31 | GBX5.00 | GBX7.50 | x |
| 2001-08-31 | GBX12.76 | GBX7.50 | x |
| 2002-08-31 | GBX9.76 | GBX7.50 | x |
| 2003-08-31 | GBX4.82 | GBX7.50 | x |
| 2004-08-31 | GBX4.75 | GBX7.50 | x |
| 2005-08-31 | GBX8.46 | GBX7.50 | x |
| 2006-08-31 | GBX4.64 | GBX7.50 | x |
| 2007-09-30 | GBX1.92 | GBX7.50 | x |
| 2008-09-30 | GBX3.52 | GBX7.50 | x |
| 2009-09-30 | GBX1.23 | GBX7.50 | x |
| 2010-09-30 | GBX4.13 | GBX7.50 | x |
| 2011-09-30 | GBX2.30 | GBX7.50 | x |
| 2012-09-30 | GBX1.21 | GBX7.50 | x |
| 2013-09-30 | GBX0.52 | GBX7.50 | x |
| 2014-09-30 | GBX0.25 | GBX7.50 | x |
| 2015-09-30 | GBX0.18 | GBX7.50 | x |
| 2016-09-30 | GBX0.17 | GBX7.50 | x |
| 2017-09-30 | GBX0.10 | GBX7.50 | x |
| 2018-09-30 | GBX0.22 | GBX7.50 | x |
| 2019-09-30 | GBX0.17 | GBX7.50 | x |
| 2020-09-30 | GBX0.19 | GBX7.50 | x |
| 2021-09-30 | GBX0.23 | GBX7.50 | x |
| 2022-09-30 | GBX0.25 | GBX7.50 | x |
| 2023-09-30 | GBX0.24 | GBX7.50 | x |
| 2024-09-30 | GBX0.20 | GBX7.50 | x |
| 2025-09-30 | GBX0.13 | GBX7.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IXICO PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.27%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.18x
- Recent ROE (-14.07%) is above the historical average (-49.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 0.00% | -238.41% | 0.67x | 0.00x | GBX-668.80K |
| 1994 | 0.00% | -1639.55% | 0.71x | 0.00x | GBX-1.93 Million |
| 1995 | 0.00% | 16.97% | 3.29x | 0.00x | GBX441.00K |
| 1996 | -5.92% | -60.49% | 0.09x | 1.04x | GBX-1.52 Million |
| 1997 | -47.31% | -6811.11% | 0.01x | 1.12x | GBX-3.71 Million |
| 1998 | -123.02% | -509.68% | 0.19x | 1.26x | GBX-3.93 Million |
| 1999 | -156.36% | -131.63% | 0.76x | 1.55x | GBX-3.43 Million |
| 2000 | -45.86% | -105.05% | 0.36x | 1.20x | GBX-2.66 Million |
| 2001 | -20.26% | -180.35% | 0.10x | 1.08x | GBX-3.96 Million |
| 2002 | -31.94% | -121.04% | 0.22x | 1.19x | GBX-4.31 Million |
| 2003 | -104.04% | -218.50% | 0.35x | 1.36x | GBX-5.81 Million |
| 2004 | -117.65% | -580.78% | 0.14x | 1.43x | GBX-6.76 Million |
| 2005 | -28.15% | -45.08% | 0.52x | 1.19x | GBX-4.51 Million |
| 2006 | -87.04% | -299.47% | 0.23x | 1.27x | GBX-6.29 Million |
| 2007 | -207.56% | -186.25% | 0.75x | 1.48x | GBX-6.09 Million |
| 2008 | -31.77% | -86.73% | 0.31x | 1.19x | GBX-2.99 Million |
| 2009 | -124.67% | -451.10% | 0.18x | 1.56x | GBX-4.22 Million |
| 2010 | -16.19% | -545.48% | 0.03x | 1.05x | GBX-6.15 Million |
| 2011 | -47.97% | -11429.85% | 0.00x | 1.16x | GBX-9.25 Million |
| 2012 | -92.75% | -41493.34% | 0.00x | 1.26x | GBX-8.60 Million |
| 2013 | -132.75% | -47670.00% | 0.00x | 1.43x | GBX-5.13 Million |
| 2014 | -45.09% | -67.15% | 0.47x | 1.42x | GBX-2.10 Million |
| 2015 | -44.08% | -38.33% | 0.73x | 1.56x | GBX-1.46 Million |
| 2016 | -51.87% | -64.84% | 0.58x | 1.39x | GBX-2.53 Million |
| 2017 | -57.16% | -37.49% | 0.91x | 1.68x | GBX-1.81 Million |
| 2018 | -9.12% | -12.38% | 0.52x | 1.41x | GBX-1.40 Million |
| 2019 | 5.46% | 5.71% | 0.71x | 1.35x | GBX-359.90K |
| 2020 | 10.44% | 9.99% | 0.79x | 1.33x | GBX40.10K |
| 2021 | 13.17% | 16.45% | 0.64x | 1.24x | GBX364.10K |
| 2022 | 8.26% | 11.94% | 0.59x | 1.17x | GBX-217.30K |
| 2023 | -10.30% | -17.67% | 0.51x | 1.14x | GBX-2.32 Million |
| 2024 | -21.14% | -34.70% | 0.52x | 1.18x | GBX-2.95 Million |
| 2025 | -14.07% | -25.27% | 0.47x | 1.18x | GBX-2.82 Million |
Industry Comparison
This section compares IXICO PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,957,694
- Average return on equity (ROE) among peers: -292.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IXICO PLC (IXI) | GBX10.72 Million | 0.00% | 0.21x | $199.82K |
| 4BASEBIO UK SOCIETAS (4BB) | $15.46 Million | -4.65% | 0.15x | $904.35K |
| Aptamer Group PLC (APTA) | $304.00K | -2577.63% | 8.06x | $105.01K |
| Arecor Therapeutics PLC (AREC) | $670.33K | -166.97% | 2.08x | $395.07K |
| Avacta Group PLC (AVCT) | $15.55 Million | -9.78% | 0.14x | $4.15 Million |
| BSF Enterprise Plc (BSFA) | $2.72 Million | -40.97% | 0.11x | $15.62K |
| Bioventix (BVXP) | $2.68 Million | 33.03% | 0.07x | $979.00K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $2.64 Million | -34.55% | 0.05x | $72.34K |
| CRISM Therapeutics Corporation (CRTX) | $-759.66K | 0.00% | 0.00x | $93.94K |
| Fusion Antibodies PLC (FAB) | $1.79 Million | -124.15% | 0.35x | $152.12K |
| Faron Pharmaceuticals Oy (FARN) | $-11.48 Million | 0.00% | 0.00x | $485.05K |
About IXICO PLC
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imag… Read more